Florida Senate - 2025 COMMITTEE AMENDMENT
Bill No. SB 1800
Ì614080xÎ614080
LEGISLATIVE ACTION
Senate . House
Comm: RCS .
04/02/2025 .
.
.
.
—————————————————————————————————————————————————————————————————
—————————————————————————————————————————————————————————————————
The Committee on Health Policy (Calatayud) recommended the
following:
1 Senate Amendment (with title amendment)
2
3 Delete everything after the enacting clause
4 and insert:
5 Section 1. Section 1004.4352, Florida Statutes, is created
6 to read:
7 1004.4352 Parkinson’s disease research.—
8 (1) SHORT TITLE.—This section may be cited as the
9 “Parkinson’s Disease Research Act.”
10 (2) LEGISLATIVE FINDINGS.—The Legislature finds that:
11 (a) Parkinson’s disease is a progressive neurological
12 disorder affecting approximately one million Americans, with an
13 estimated 90,000 new diagnoses each year.
14 (b) Currently, there is no cure for Parkinson’s disease,
15 and innovative research is essential to advance therapies,
16 improve patient outcomes, and alleviate the burden of the
17 disease.
18 (3) DEFINITIONS.—As used in this section, the term:
19 (a) “Board” means the Parkinson’s Disease Research Board.
20 (b) “Consortium” means the Consortium for Parkinson’s
21 Disease Research.
22 (4) CONSORTIUM FOR PARKINSON’S DISEASE RESEARCH.—
23 (a) There is established within the University of South
24 Florida the Consortium for Parkinson’s Disease Research which
25 shall consist of public and private universities. The purpose of
26 the consortium is to conduct rigorous scientific research and
27 disseminate such research.
28 (b) The Parkinson’s Disease Research Board is established
29 to direct the operations of the consortium. The board shall be
30 composed of members representing each participating university
31 and appointed by the president of each participating university.
32 Board members must have experience in a variety of scientific
33 fields, including, but not limited to, neurology, psychology,
34 nutrition, and genetics. Members shall be appointed to 4-year
35 terms and may be reappointed to serve additional terms. The
36 chair shall be elected by the board from among its members to
37 serve a 2-year term. The board shall meet at least semiannually
38 at the call of the chair or, in his or her absence or
39 incapacity, the vice chair. Four members constitute a quorum. A
40 majority vote of the members present is required for all actions
41 of the board. The board may prescribe, amend, and repeal a
42 charter governing the manner in which it conducts its business.
43 Board members shall serve without compensation, but are entitled
44 to receive reimbursement for travel expenses by the consortium
45 or the organization he or she represents in accordance with s.
46 112.061.
47 (c) The consortium shall be administered by a director, who
48 shall be appointed by and serve at the pleasure of the board.
49 The director shall, subject to the approval of the board:
50 1. Propose a budget for the consortium.
51 2. Foster the collaboration of scientists, researchers, and
52 other appropriate personnel in accordance with the consortium’s
53 charter.
54 3. Engage individuals in public and private university
55 programs relevant to the consortium’s work to participate in the
56 consortium.
57 4. Identify and prioritize the research to be conducted by
58 the consortium.
59 5. Prepare a plan for Parkinson’s disease research for
60 submission to the board.
61 6. Apply for grants to obtain funding for research
62 conducted by the consortium.
63 7. Perform other duties as determined by the board.
64 (d) The board shall annually adopt a plan for Parkinson’s
65 disease research. The plan must organize a program of research
66 that contributes to the body of scientific knowledge on the
67 causes, mechanisms, and potential treatments for Parkinson’s
68 disease and the prevalence of Parkinson’s disease in first
69 responders. The board must award funds to members of the
70 consortium to perform research consistent with the plan.
71 (e) By October 15 of each year, the board shall issue a
72 report to the Governor, the President of the Senate, and the
73 Speaker of the House of Representatives on research projects,
74 research findings, community outreach initiatives, and future
75 plans for the consortium.
76 Section 2. (1) Subject to appropriations from the General
77 Appropriations Act, 67 percent of funds appropriated are
78 directed to the University of South Florida for Parkinson’s
79 disease research including, but not limited to, identifying the
80 genetic origin of the disease and developing therapeutic
81 interventions to slow or stop the progression of the disease.
82 (2) Subject to appropriations from the General
83 Appropriations Act, 33 percent of funds appropriated are
84 directed to the University of South Florida for the Consortium
85 for Parkinson’s Disease Research.
86 Section 3. This act shall take effect July 1, 2025.
87
88 ================= T I T L E A M E N D M E N T ================
89 And the title is amended as follows:
90 Delete everything before the enacting clause
91 and insert:
92 A bill to be entitled
93 An act relating to Parkinson’s disease; creating s.
94 1004.4352, F.S.; providing a short title; providing
95 legislative findings; defining terms; establishing the
96 Consortium for Parkinson’s Disease Research within the
97 University of South Florida; establishing the
98 Parkinson’s Disease Research Board; providing for the
99 membership of the board; requiring the board to direct
100 the operations of the consortium and to annually adopt
101 a plan for Parkinson’s disease research; providing
102 duties of the consortium director; providing research
103 requirements for the plan; requiring the board to
104 award funds to board members for certain purposes;
105 requiring the board to issue an annual report to the
106 Governor and Legislature by a specified date;
107 providing appropriations; providing an effective date.